Optimize Your Health - Available Everywhere in the US

  188-8981-6784    HIPAA Compliant  ยท  Licensed U.S. Providers

OptiMale USA โ€” Peptide Regulatory // Last Updated April 2026

Regulatory Updates

The FDA regulatory landscape for peptide compounding has shifted significantly since early 2024. We track every major development so our patients stay informed. All compounds listed below are available at OptiMale under physician-supervised protocols.

OptiMale ยท Peptide Therapy

Regulatory Updates

The FDA regulatory landscape for peptide compounding has shifted significantly since early 2024. We track every major development so our patients stay informed. All compounds listed below are available at OptiMale under physician-supervised protocols.

Last updated: April 2026
Feb
2026
Latest Update
HHS Secretary Kennedy Announces 14 Restricted Peptides to Return to Legal Compounding Access

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced on the Joe Rogan Experience that approximately 14 of the 19 peptides placed on the FDA's Category 2 restricted list in 2023 are expected to move back to Category 1 โ€” restoring the legal pathway for licensed compounding pharmacies to prepare them under physician prescription. Kennedy indicated the change would happen within weeks of the announcement. As of April 2026 the formal FDA publication is still pending, but the regulatory direction is clear. All compounds below are currently available at OptiMale under physician supervision.

Compounds Affected โ€” Available at OptiMale
Oct
2024
PCAC Review
FDA Advisory Committee Begins Formal Scientific Review of Key Peptides

At the October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) meeting, the FDA began formal scientific review of several high-demand peptides for potential inclusion in the 503A Bulks Regulation โ€” the regulatory framework that permits licensed compounding pharmacies to prepare customized prescriptions under physician supervision. Each compound is evaluated on its full clinical, pharmacological, and safety evidence. This review is the formal pathway through which these compounds regain legal compounding status.

Compounds Under Formal Review โ€” Available at OptiMale
Sep
2024
Restriction Lifted
Five Peptides Removed from FDA Category 2 Restricted List

On September 20, 2024, the FDA announced that five peptide bulk drug substances were being removed from Category 2 following the withdrawal of their original restriction nominations. Effective September 27, 2024, these compounds entered the formal PCAC review pipeline for full reclassification to Category 1, making them the furthest along in the reinstatement process. All five are currently available at OptiMale under physician-supervised protocols.

Compounds Removed from Restricted List โ€” Available at OptiMale
Important: Regulatory status information is provided for educational purposes only and reflects publicly available information as of April 2026. Removal from Category 2 or pending reclassification does not constitute FDA approval of any compound for any indication. All peptide therapies at OptiMale are administered under the supervision of a licensed physician as part of individualized treatment protocols. Regulatory classifications are subject to change; consult your OptiMale physician for the most current guidance.
Ready to start?

Meet Your Provider. Free.

Your first consultation is complimentary. No pressure, no obligation โ€” just an honest assessment of where you are and where you could be.

These statements have not been evaluated by the Food and Drug Administration. The information on this website is provided for educational and informational purposes only and does not constitute medical advice, a diagnosis, a treatment recommendation, or an offer to prescribe, supply, compound, administer, or dispense any product.

Compounded medications. Compounded medications, including compounded semaglutide and compounded tirzepatide, are not FDA-approved and are not generic equivalents of brand-name products such as Ozempicยฎ, Wegovyยฎ, Mounjaroยฎ, or Zepboundยฎ. The FDA does not review compounded drugs for safety, effectiveness, or quality prior to dispensing. Compounded medications are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities pursuant to a valid prescription from a licensed provider following individual patient evaluation. Availability of compounded medications varies by state and is subject to applicable state and federal law.

Research compounds. Certain compounds referenced on this website are research compounds that are not approved by the FDA for human use and have not been evaluated by the FDA for safety, efficacy, or quality. Information about these compounds is provided solely for educational and informational purposes and reflects publicly available scientific literature. OptiMale USA and its affiliated providers do not prescribe, supply, recommend, compound, administer, or dispense research compounds, and nothing on this website should be construed as an offer to do so. Patient consent forms purporting to waive provider duty of care with respect to research compounds are not recognized as a defense to professional liability and are not used by OptiMale USA.

Clinical services. All prescription products and services offered through OptiMale USA are prescribed exclusively by board-certified, licensed U.S. providers following individual clinical evaluation, comprehensive bloodwork where indicated, and a detailed health assessment. Available services and products vary by state based on provider licensure and applicable law. No provider-patient relationship is established by use of this website; a provider-patient relationship is formed only upon completion of a clinical evaluation with a licensed OptiMale USA provider.

Individual results vary. Always consult a qualified healthcare provider before beginning any new health protocol.

  • Home
  • Products
  • Solutions
  • How it Works
  • Peptide Library